HUTCHMED CHINA-ADR (HCM) Fundamental Analysis & Valuation

NASDAQ:HCM • US44842L1035

Current stock price

13.81 USD
-0.35 (-2.47%)
Last:

This HCM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. HCM Profitability Analysis

1.1 Basic Checks

  • In the past year HCM was profitable.
  • HCM had a negative operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: HCM reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: HCM reported negative operating cash flow in multiple years.
HCM Yearly Net Income VS EBIT VS OCF VS FCFHCM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M

1.2 Ratios

  • The Return On Assets of HCM (26.06%) is better than 98.96% of its industry peers.
  • HCM's Return On Equity of 36.91% is amongst the best of the industry. HCM outperforms 96.37% of its industry peers.
Industry RankSector Rank
ROA 26.06%
ROE 36.91%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HCM Yearly ROA, ROE, ROICHCM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • HCM has a Profit Margin of 83.30%. This is amongst the best in the industry. HCM outperforms 98.96% of its industry peers.
  • HCM has a better Gross Margin (38.68%) than 62.18% of its industry peers.
  • HCM's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 83.3%
GM 38.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.67%
GM growth 5Y17.45%
HCM Yearly Profit, Operating, Gross MarginsHCM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. HCM Health Analysis

2.1 Basic Checks

  • HCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 5 years ago, HCM has more shares outstanding
HCM Yearly Shares OutstandingHCM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2025 50M 100M 150M
HCM Yearly Total Debt VS Total AssetsHCM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2025 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 3.56 indicates that HCM is not in any danger for bankruptcy at the moment.
  • HCM has a Altman-Z score of 3.56. This is in the better half of the industry: HCM outperforms 73.06% of its industry peers.
  • A Debt/Equity ratio of 0.08 indicates that HCM is not too dependend on debt financing.
  • The Debt to Equity ratio of HCM (0.08) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 3.56
ROIC/WACCN/A
WACC9.52%
HCM Yearly LT Debt VS Equity VS FCFHCM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 4.96 indicates that HCM has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 4.96, HCM is doing good in the industry, outperforming 65.28% of the companies in the same industry.
  • A Quick Ratio of 4.83 indicates that HCM has no problem at all paying its short term obligations.
  • HCM's Quick ratio of 4.83 is fine compared to the rest of the industry. HCM outperforms 65.80% of its industry peers.
Industry RankSector Rank
Current Ratio 4.96
Quick Ratio 4.83
HCM Yearly Current Assets VS Current LiabilitesHCM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. HCM Growth Analysis

3.1 Past

  • HCM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1109.24%, which is quite impressive.
  • Looking at the last year, HCM shows a very negative growth in Revenue. The Revenue has decreased by -12.96% in the last year.
  • Measured over the past years, HCM shows a quite strong growth in Revenue. The Revenue has been growing by 19.20% on average per year.
EPS 1Y (TTM)1109.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-83.94%
Revenue 1Y (TTM)-12.96%
Revenue growth 3Y8.76%
Revenue growth 5Y19.2%
Sales Q2Q%-16.54%

3.2 Future

  • Based on estimates for the next years, HCM will show a very negative growth in Earnings Per Share. The EPS will decrease by -24.38% on average per year.
  • Based on estimates for the next years, HCM will show a very strong growth in Revenue. The Revenue will grow by 25.98% on average per year.
EPS Next Y-83.17%
EPS Next 2Y-50.35%
EPS Next 3Y-24.38%
EPS Next 5YN/A
Revenue Next Year16.12%
Revenue Next 2Y16.81%
Revenue Next 3Y20.99%
Revenue Next 5Y25.98%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HCM Yearly Revenue VS EstimatesHCM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
HCM Yearly EPS VS EstimatesHCM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

3

4. HCM Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 5.19, which indicates a rather cheap valuation of HCM.
  • Based on the Price/Earnings ratio, HCM is valued cheaper than 95.85% of the companies in the same industry.
  • HCM's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.88.
  • The Price/Forward Earnings ratio is 31.95, which means the current valuation is very expensive for HCM.
  • 71.50% of the companies in the same industry are more expensive than HCM, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of HCM to the average of the S&P500 Index (22.19), we can say HCM is valued slightly more expensively.
Industry RankSector Rank
PE 5.19
Fwd PE 31.95
HCM Price Earnings VS Forward Price EarningsHCM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HCM Per share dataHCM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as HCM's earnings are expected to decrease with -24.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-50.35%
EPS Next 3Y-24.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HCM Dividend Analysis

5.1 Amount

  • No dividends for HCM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HCM Fundamentals: All Metrics, Ratios and Statistics

HUTCHMED CHINA-ADR

NASDAQ:HCM (3/27/2026, 8:23:15 PM)

13.81

-0.35 (-2.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-05
Earnings (Next)08-05
Inst Owners19.35%
Inst Owner Change-10.44%
Ins Owners0.58%
Ins Owner Change0%
Market Cap2.37B
Revenue(TTM)548.51M
Net Income(TTM)456.91M
Analysts84.17
Price Target16.64 (20.49%)
Short Float %0.32%
Short Ratio8.58
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)3.29%
EPS NY rev (3m)3.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.38%
Valuation
Industry RankSector Rank
PE 5.19
Fwd PE 31.95
P/S 4.33
P/FCF N/A
P/OCF N/A
P/B 1.92
P/tB 1.92
EV/EBITDA N/A
EPS(TTM)2.66
EY19.26%
EPS(NY)0.43
Fwd EY3.13%
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS3.19
BVpS7.2
TBVpS7.18
PEG (NY)N/A
PEG (5Y)N/A
Graham Number20.76
Profitability
Industry RankSector Rank
ROA 26.06%
ROE 36.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 83.3%
GM 38.68%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.67%
GM growth 5Y17.45%
F-ScoreN/A
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 181.46%
Cap/Sales 4.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.96
Quick Ratio 4.83
Altman-Z 3.56
F-ScoreN/A
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)241.38%
Cap/Depr(5y)276.07%
Cap/Sales(3y)3.71%
Cap/Sales(5y)4.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1109.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-83.94%
EPS Next Y-83.17%
EPS Next 2Y-50.35%
EPS Next 3Y-24.38%
EPS Next 5YN/A
Revenue 1Y (TTM)-12.96%
Revenue growth 3Y8.76%
Revenue growth 5Y19.2%
Sales Q2Q%-16.54%
Revenue Next Year16.12%
Revenue Next 2Y16.81%
Revenue Next 3Y20.99%
Revenue Next 5Y25.98%
EBIT growth 1Y10.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.6%
EBIT Next 3Y79.44%
EBIT Next 5YN/A
FCF growth 1Y-409.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13109.5%
OCF growth 3YN/A
OCF growth 5YN/A

HUTCHMED CHINA-ADR / HCM Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for HUTCHMED CHINA-ADR?

ChartMill assigns a fundamental rating of 4 / 10 to HCM.


Can you provide the valuation status for HUTCHMED CHINA-ADR?

ChartMill assigns a valuation rating of 3 / 10 to HUTCHMED CHINA-ADR (HCM). This can be considered as Overvalued.


Can you provide the profitability details for HUTCHMED CHINA-ADR?

HUTCHMED CHINA-ADR (HCM) has a profitability rating of 4 / 10.


What are the PE and PB ratios of HUTCHMED CHINA-ADR (HCM) stock?

The Price/Earnings (PE) ratio for HUTCHMED CHINA-ADR (HCM) is 5.19 and the Price/Book (PB) ratio is 1.92.


Can you provide the expected EPS growth for HCM stock?

The Earnings per Share (EPS) of HUTCHMED CHINA-ADR (HCM) is expected to decline by -83.17% in the next year.